利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.014 秒)

    RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FILOVIRUS VACCINE
    2.
    发明公开
    RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FILOVIRUS VACCINE 审中-公开
    重组修饰的痘苗病毒安卡拉（MVA）膜状病毒疫苗

    公开(公告)号：EP3188752A2

    公开(公告)日：2017-07-12

    申请号：EP15763853.7

    申请日：2015-09-03

    申请人： Bavarian Nordic A/S

    发明人： VOLKMANN, Ariane ,  STEIGERWALD, Robin ,  HOCHREIN, Hubertus ,  DIRMEIER, Ulrike ,  LAUTERBACH, Henning ,  HAUSMANN, Jürgen

    IPC分类号： A61K39/12

    CPC分类号： A61K39/12 ,  A61K2039/545 ,  C12N7/00 ,  C12N2710/24143 ,  C12N2760/14134

    摘要： The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.

    摘要翻译： 本发明涉及包含针对丝状病毒感染的基于重组修饰的痘苗病毒安卡拉（基于MVA的）疫苗的改进的丝状病毒疫苗，并涉及相关产品，方法和用途。 具体而言，本发明涉及包含至少一种编码马尔堡病毒（MARV）或埃博拉病毒糖蛋白的抗原决定簇的异源核苷酸序列的基因工程（重组）MVA和FPV载体。 具体而言，本发明涉及包含埃博拉病毒糖蛋白和病毒粒子蛋白40的重组MVA。本发明还涉及其产品，方法和用途以及MVA和基因工程（重组）FPV的初免/加强方案，例如适于诱导 受试者中的保护性免疫应答。

    POXVIRUS VECTOR FOR THE EXPRESSION OF BACTERIAL ANTIGENS LINKED TO TETANUS TOXIN FRAGMENT C
    3.
    发明公开
    POXVIRUS VECTOR FOR THE EXPRESSION OF BACTERIAL ANTIGENS LINKED TO TETANUS TOXIN FRAGMENT C 有权
    POCKENVIRUS-VEKTOR ZUR EXPRESSION VON BAKTERIELLEN抗原，WELCHE MIT TETANUS TOXIN FRAGMENT C VERBUNDEN SIND

    公开(公告)号：EP2788021A1

    公开(公告)日：2014-10-15

    申请号：EP12794878.4

    申请日：2012-11-30

    申请人： Bavarian Nordic A/S

    发明人： CHAPLIN, Paul ,  STEIGERWALD, Robin

    IPC分类号： A61K39/02 ,  C12N15/86

    CPC分类号： C12N15/86 ,  A61K39/07 ,  A61K2039/53 ,  A61K2039/6037 ,  C07K2319/55 ,  C12N2710/24043 ,  C12N2710/24143

    摘要： The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject.

    摘要翻译： 本发明涉及包含用于改善抗原免疫原性的破伤风毒素片段C和相关方法和用途的重组痘病毒。 具体而言，本发明通常涉及包含可操作地连接到细菌抗原决定簇的破伤风毒素片段C（TTC）编码序列的基因工程（重组）痘病毒载体及其用途，例如影响受试者的免疫应答 。

    POXVIRAL VECTORS FOR LOW ANTIBODY RESPONSE AFTER A FIRST PRIMING IMMUNIZATION
    8.
    发明公开
    POXVIRAL VECTORS FOR LOW ANTIBODY RESPONSE AFTER A FIRST PRIMING IMMUNIZATION 审中-公开
    POXVIRUS-VEKTORENFÜRNIEDRIGE防盗报警器NACH EINER ERSTEN GRUNDIMMUNISIERUNG

    公开(公告)号：EP2864487A1

    公开(公告)日：2015-04-29

    申请号：EP13730812.8

    申请日：2013-06-21

    申请人： Bavarian Nordic A/S

    发明人： STEIGERWALD, Robin ,  BRINKMANN, Kay ,  DIRMEIER, Ulrike ,  CHAPLIN, Paul

    IPC分类号： C12N15/86

    CPC分类号： A61K39/285 ,  A61K2039/53 ,  C12N7/00 ,  C12N15/11 ,  C12N15/86 ,  C12N2710/24122 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2830/60

    摘要： The invention is drawn to compositions and methods for the induction of an immune response, in particular a strong CD8 T cell response, to a specific antigenic determinant without raising a significant antibody response to the antigenic determinant after a first, priming immunization. The method comprises administering to the host a recombinant poxviral vector comprising a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The recombinant poxviral vector comprises a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The late element may be stronger than the cowpox ATI promoter in HeLa cells.

    摘要翻译： 本发明涉及用于诱导特异性抗原决定簇的免疫应答特别是强CD8T细胞应答的组合物和方法，而不会在第一次启动免疫后对抗原决定簇产生显着的抗体应答。 该方法包括向宿主施用包含转录控制元件的重组痘病毒载体，其包含与编码抗原决定簇的核苷酸序列连接的早期和/或晚期元件。 重组痘病毒载体包含转录控制元件，其包含与编码抗原决定簇的核苷酸序列连接的早期和/或晚期元件。 晚期元件可能比HeLa细胞中的牛痘ATI启动子更强。